
Sign up to save your podcasts
Or


Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, the approval of the first drug to treat a devastating rare disease, and the bankruptcy of 23andMe. Then, they bring on the chief executive of startup Altis Labs to discuss new data from a study they conducted with AstraZeneca on an AI tool for cancer drug development.
By STAT4.5
309309 ratings
Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, the approval of the first drug to treat a devastating rare disease, and the bankruptcy of 23andMe. Then, they bring on the chief executive of startup Altis Labs to discuss new data from a study they conducted with AstraZeneca on an AI tool for cancer drug development.

30,782 Listeners

1,952 Listeners

493 Listeners

9,551 Listeners

6,066 Listeners

388 Listeners

62 Listeners

85 Listeners

34 Listeners

522 Listeners

5,524 Listeners

21 Listeners

50 Listeners

400 Listeners

12 Listeners